DeeperML - #alphafold

Isomorphic Labs, an Alphabet spinout focused on AI-driven drug design, has secured $600 million in its first external funding round. The investment, led by Thrive Capital with participation from Alphabet and GV, will fuel the advancement of Isomorphic Labs' AI drug design engine and therapeutic programs. The company aims to leverage artificial intelligence, including its AlphaFold technology, to revolutionize drug discovery across various therapeutic areas, including oncology and immunology. This funding is expected to accelerate research and development efforts, as well as facilitate the expansion of Isomorphic Labs' team with top-tier talent.

Isomorphic Labs, founded in 2021 by Sir Demis Hassabis, seeks to reimagine and accelerate drug discovery by applying AI. Its AI-powered engine streamlines the design of small molecules with therapeutic applications and can predict the effectiveness of a small molecule's attachment to a protein. The company's software also eases other aspects of the drug development workflow. Isomorphic Labs has already established collaborations with pharmaceutical companies like Eli Lilly and Novartis, and the new funding will support the progression of its own drug programs into clinical development.


References :

• www.genengnews.com: DeepMind Spinout Isomorphic Labs Raises $600M Toward AI Drug Design
• Crunchbase News: Alphabet-Backed Isomorphic Labs Raises $600M For AI Drug Development
• Maginative: Isomorphic Labs Secures $600M to Accelerate AI-Powered Drug Discovery
• AI ? SiliconANGLE: Alphabet spinout Isomorphic Labs raises $600M for its AI drug design engine
• Silicon Canals: London-based Isomorphic Labs, an AI-focused drug design and development company, has raised $600M (nearly €555.44M) in its first external funding round.
• GZERO Media: Meet Isomorphic Labs, the Google spinoff that aims to cure you
• www.genengnews.com: DeepMind Spinout Isomorphic Labs Raises $600M Toward AI Drug Design
• Maginative: AI-first drug design company Isomorphic Labs has raised $600 million in its first external funding round, led by Thrive Capital, to advance its AI drug design engine and therapeutic programs.
• eWEEK: AI drug design and development company Isomorphic Labs announced on Monday that it raised $600 million in its first external funding round. Thrive Capital led the financing round with participation from Google’s GV, and follow-on capital from Alphabet, its parent company and an existing investor. Isomorphic Labs described plans to use the funds to drive

Classification:

• HashTags: #AIDrugDiscovery #IsomorphicLabs #AlphaFold
• Company: Alphabet
• Target: Healthcare
• Product: AlphaFold
• Feature: AI Drug Design Engine
• Type: AI
• Severity: Informative

DeepMind has announced significant advancements in AI modeling and biomedicine, pushing the boundaries of what's possible with artificial intelligence. The company's research is focused on creating more effective drugs and medicine, as well as understanding and protecting species around the world.

DeepMind's JetFormer, a novel Transformer model, is designed to directly model raw data, eliminating the need for pre-trained components. JetFormer can understand and generate both text and images seamlessly. This model leverages normalizing flows to encode images into a latent representation, enhancing the focus on essential high-level information through progressive Gaussian noise augmentation. JetFormer has demonstrated competitive performance in image generation and web-scale multimodal generation tasks.

Additionally, DeepMind is exploring how studying honeybee immunity could offer insights into protecting various species. The company's AlphaFold continues to revolutionize biology, aiding in the design of more effective drugs. AlphaFold, which uses AI to determine a protein's structure, has been used to solve fundamental questions in biology, awarded the Nobel prize (in chemistry – to Demis Hassabis and John Jumper) and revolutionised drug discovery. There are approximately 250,000,000 protein structures in the AlphaFold database, which has been used by almost 2 million people from 190 countries.


References :

• Synced: DeepMind’s JetFormer: Unified Multimodal Models Without Modelling Constraints
• www.theguardian.com: AI may help us cure countless diseases – and usher in a new golden age of medicine | Samuel Hume

Classification:

• HashTags: #DeepMind #JetFormer #AlphaFold
• Company: Google DeepMind
• Target: AI researchers
• Product: AlphaFold, JetFormer
• Feature: Multimodal models, Drug discov
• Type: AI
• Severity: Informative